https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=14623

Elvitegravir / Cobicistat

Glimepiride

Dosage adjustment may be necessary.

No pharmaceutical opinion available for this interaction.

Mechanism

Elvitegravir / Cobicistat can induce the metabolism (CYP 2C9) and decrease the plasma concentration of Glimepiride.

Elvitegravir / Cobicistat

Pharmacodynamic effects

–

Recommendations

–

Alternative solution(s)

–

Glimepiride

Pharmacodynamic effects

Possible decrease of clinical efficacy.

Recommendations

Monitor for clinical efficacy and adjust the dosage if necessary.

Alternative solution(s)

Metformin, DPP-4 Inhibitors, GLP-1 Agonists

Monitor

–

Tests

Blood Sugar

Pharmacokinetic parameters

–

Comment

Ref #3189 : Co-administration of 600 mg rifampicin, a CYP2C9 inducer, and a single dose of glimepiride 1 mg (after 7 days of once daily rifampicin 600 mg) resulted in a 34% in glimepiride AUC. However, no effect on blood glucose was observed in this study.

Reference
  • 3188
    Glimepiride (Amaryl), Sanofi-Aventis, Québec, Canada, 23 décembre 2016.
  • 3189
    Niemi M, Kivistö KT, Backman JT, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. J Clin Pharmacol 2000; 50: 591-5.